Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

the fastest-growing segment for Novo Nordisk. This past 2024, despite a 33% drop in Saxenda sales, this area grew by 56%, driven by the incredible 85% annual growth of Wegovy. Even with increasing ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic and Wegovy, used a submission to the government’s budget process to push for the inclusion of so-called GLP-1 drugs on the PBS ...

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance in the final quarter of last year, helping to drive group revenue growth of 30% – but don't expect that breakneck ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Novo Nordisk defiende fármaco contra la obesidad de próxima generación CagriSema, detalla nuevo ensayo February 5, 2025 Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald ...